UBS Group’s Boundless Bio BOLD Stock Holding History

UBS Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Sell	2 -21	-91%	-$25	﹤0.01%	10377
2025 Q4	$27	Buy	23 +22	+2,200%	+$27	﹤0.01%	10330
2025 Q3	$1	Sell	1 -12	-92%	-$14	﹤0.01%	10273
2025 Q2	$13	Sell	13 -7,557	-100%	-$10K	﹤0.01%	10143
2025 Q1	$11.4K	Sell	7,570 -8,379	-53%	-$17.4K	﹤0.01%	8555
2024 Q4	$46.3K	Buy	15,949 +12,971	+436%	+$37.8K	﹤0.01%	7349
2024 Q3	$10.3K	Buy	2,978 +1,063	+56%	+$3.85K	﹤0.01%	7733
2024 Q2	$7.41K	Buy	+1,915	New	+$18.3K	﹤0.01%	7854

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

UBS Group's BOLD Position: Q1 2026 in Review

UBS Group reduced its Boundless Bio (BOLD) stake by 91% in Q1 2026, selling an estimated $25 and leaving 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #10377.

UBS Group first reported a position in BOLD in Q2 2024 and has held it in 8 quarters since. The position peaked at $46.3K in Q4 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

UBS Group held 2 shares of Boundless Bio worth $2 as of Q1 2026.
UBS Group sold 21 Boundless Bio shares in Q1 2026, an estimated $25.
Boundless Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10377 holding.
UBS Group first reported a position in Boundless Bio in Q2 2024 and has held it in 8 quarters since.
UBS Group's Boundless Bio position peaked at $46.3K in Q4 2024.
36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.